Preoperative neutrophil-to-lymphocyte ratio (NLR) value as a predictor of recurrence of non-muscle-invasive bladder cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The neutrophil-to-lymphocyte ratio (NLR) can predict non-muscle-invasive bladder cancer recurrence. An NLR value greater than 1.73 indicates a higher risk, aiding in treatment selection for high-risk patients.
Area Of Science
- Oncology
- Urology
Background
- Neutrophil-to-lymphocyte ratio (NLR) is explored as a predictor for oncological outcomes in non-muscle-invasive bladder cancer (NMIBC).
- Accurate prediction is crucial for selecting appropriate treatments for NMIBC patients.
Purpose Of The Study
- To determine if NLR is an independent predictor of disease progression and recurrence in NMIBC.
- To evaluate the prognostic value of preoperative NLR in NMIBC patients.
Main Methods
- Prospective study of 99 newly diagnosed NMIBC patients from March 2018 to March 2023.
- Preoperative NLR values were monitored following trans-urethral resection of bladder tumor (TURBT) and adjuvant intravesical therapy.
- ROC curve and Youden index identified optimal NLR cutoff for recurrence prediction over a 24-month follow-up.
Main Results
- A statistically significant correlation (p=0.008) was found between NLR values and increased recurrence risk, with a cutoff of 1.73.
- Univariate and multivariate Cox regression analyses confirmed NLR's significant prognostic impact on disease recurrence.
Conclusions
- An NLR value exceeding 1.73 is a significant preoperative predictor for NMIBC.
- This finding aids in risk assessment and treatment selection for intermediate- and high-risk NMIBC patient groups.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.